---
title: "China Accepts Hansoh Pharmaceutical's Socrodeucitinib Application for Psoriasis Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306260164.md"
description: "China's National Medical Products Administration accepted Hansoh Pharmaceutical's new drug application for socrodeucitinib tablets (HS-10374) on November 20, 2026. The treatment targets adults with moderate-to-severe plaque psoriasis."
datetime: "2026-11-20T10:31:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306260164.md)
  - [en](https://longbridge.com/en/news/306260164.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306260164.md)
generator: "portal-rs"
---

# China Accepts Hansoh Pharmaceutical's Socrodeucitinib Application for Psoriasis Treatment

-   China’s National Medical Products Administration accepted Hansoh Pharmaceutical’s new drug application for socrodeucitinib tablets (HS-10374) for review on November 20, 2026. \* The treatment targets adults with moderate-to-severe plaque psoriasis. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261120-12420552), on November 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)

## Related News & Research

- [Hansoh Adds Three Innovative-Medicine Indications to 2026 NRDL](https://longbridge.com/en/news/305581132.md)
- [Hansoh's Aumolertinib Wins EMA Panel Backing for EU Marketing Authorization](https://longbridge.com/en/news/305569307.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [Hansoh Pharma's dalmelitinib-aumolertinib improves progression-free survival in Phase 3 lung cancer trial](https://longbridge.com/en/news/303061643.md)
- [Moonshot drops $150M Indonesia Nvidia rental days after US loophole crackdown](https://longbridge.com/en/news/306145817.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**